Humanigen, Inc. is a clinical-stage biopharmaceutical firm dedicated to combating “cytokine storm,” an immune overreaction. Their key product, lenzilumab, neutralizes the GM-CSF (granulocyte-macrophage colony-stimulating factor) through binding to it. The company is working towards getting lenzilumab approved as a treatment for cytokine storm related to COVID-19, having completed a Phase 3 study and is part of a Phase 2/3 study supported by the National Institutes of Health (NIH). Lenzilumab is also being studied in combination with CAR-T cell therapies that target CD19, as well as for its effectiveness in treating various inflammatory conditions such as acute Graft versus Host Disease, post allogeneic hematopoietic stem cell transplantation, rheumatoid arthritis, and eosinophilic asthma.
Contents
How do we estimate HGEN will do in 2023?
HGEN has been on a downtrend since 2013, and we do not see things changing at all. With a high of 327 as of 2013 and its current price is 0.1920 in 2023, we can safely say that HGEN is a bad and very high-risk investment for individuals looking to add this stock to their portfolio.
We estimate that HGEN will be trading at $0.2300 by the end of 2023. HGEN has the potential to go much lower than its current price of $0.1920 in 2023.
We do not think that there is much that can be done to save this stock, as there have been a lot of inefficiencies in the charts and a consistent decline in price. With over 10 years of decline, there is very little to no room for recovery.
How do we estimate HGEN will do in 2024?
By 2024, we estimate that HGEN would have found a new low below $0.07, making it an all-time low. Following the trend, HGEN is down almost 100% from its All-Time High since 2013. Humanigen will likely keep finding new floor prices, this project is not ideal for individuals looking for mid – low risk stocks.
Below is a chart showing the price history of HGEN on a monthly time frame.
We estimate a new floor price and further consolidation in 2024. With regards to fundamentals, there is really nothing we are aware of that can change the direction of price.
How do we estimate HGEN will do in 2025?
We estimate that HGEN will be trading below $0.04 by 2025 with lots of imbalances and inefficiencies in price. This will be a 79% drop from the current price of $0.1920. As we all know, no one can accurately forecast future prices, and our estimates are based on historical data and technical analysis. HGEN is a bad investment for people looking for long-term investment, things may be different if we get more fundamentals in the future to generate our estimates.
How do we estimate HGEN will do in 2030?
In 2030, we estimate HGEN to be in a descending range from $0.01 to $0.005. Although things could change before then if they could become invaluable, this is unlikely, and the stock market is very unpredictable, so always prepare for the unexpected.
In 2020, HGEN stock price skyrocketed because of COVID-19, it went up by over 16X. Before 2030, we could have a catalyst that could trigger drastic changes in price. Aside from that low probability, HGEN will likely continue its downtrend and find new lows over the course of years. If you are looking for a stock to invest in, you can research better alternatives that are less likely to hurt your portfolio.
FAQ
There are several factors that can indicate that the price of a stock may increase. These include positive financial performance, such as increasing earnings and revenue, favorable industry conditions, analyst upgrades and positive guidance, company mergers and acquisitions, and positive news and developments related to the company and its products or services. However, it is important to note that stock prices can be influenced by many factors, and there is no guaranteed way to predict stock price movements. It is crucial to thoroughly research and analyze a company before making any investment decisions.
A stock’s potential to crash can be indicated by a variety of factors. Firstly, company-specific factors such as declining earnings, poor management decisions, and operational issues can all contribute to a decrease in stock value. Secondly, changes in the broader economic and market environment, such as a recession or market correction, can also impact individual stocks.